Clinical Trial Update: 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluating 12-O-tetradecanoylphorbol-13-acetate in hematologic cancers and bone marrow disorders was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms
• Plasma Cell Neoplasms
• Precancerous Conditions

Drugs mentioned

• 12-O-Tetradecanoylphorbol-13-acetate (12-O-tetradecanoylphorbol-13-acetate)

Snippet

Sponsor: University of Medicine and Dentistry of New Jersey | Conditions: Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Status: TERMINATED